Patients and Methods
EDTA plasma samples were obtained during the first 72h, on hospital admission, at 98 2h, 6h, 12h, 24h, 36h, 48h and 72h after CA. Due to missing samples in the admission 99 and 2h-sampling, these two categories were combined and the highest value was used. 100
The samples were centrifuged and frozen (-70°C) immediately after collection. After 101 the end of the study, samples were thawed once, centrifuged at 4000 rpm for 5 102 minutes, aliquoted and refrozen (-70°C) for later analysis. 103
The concentration of HBP was determined by ELISA. 21 Samples were coded and the 104 researcher performing the analysis was blinded to patient data at the time. Briefly, a 105 mouse monoclonal antibody directed against human HBP (2F23A) 22 was used at 1.0 106 µl/ml. Patient plasma samples were diluted 1/40 and each plate also contained 107 calibration samples of known concentration of recombinant human HBP. 23 Plates 108
were incubated with a polyclonal rabbit antiserum towards human HBP diluted 109
1/7000
22 and peroxidase-conjugated antibody against rabbit IgG(1/3000) (Bio-Rad, 110
Berkeley, CA, USA). 111
Epidemiological data, and CA-data were collected prospectively, as was data on 112 incidence of infection. Infection was considered present at the discretion of the 113 treating physician, as described earlier. 24 A secondary definition of infection was 114 based on the extended and restricted definitions previously used by Scheutz et al. APACHE II-scores and SOFA-scores were retrieved from the computerized system 122 for quality assurance for intensive care (PASIVA) (Otimo Data AB, Kalmar, Sweden). 123
Lactate levels and fluid balance 24h after CA were retrieved from medical records. 124
Fluid balance was categorized as either positive (≥5 litres) or normal (<5 litres). 125
Lactate was considered elevated above 2.5mmol/l which is the cut-off value at the 126 local laboratory. 127
An intensivist evaluated all patients at discharge from the ICU, and at hospital 128 discharge. Six months later, a neurologist assessed the patients using the Cerebral 129
Performance Categories scale: CPC 1: good cerebral performance, CPC 2: moderate 130 cerebral disability, independent, CPC 3: severe cerebral disability, conscious but 131 dependent, CPC 4: coma, CPC 5: death. 26 A CPC score of 1-2 at 6 months was 132 considered a good outcome and a CPC of 3-5 was considered a poor outcome. 133
Study population 134
All cardiac arrest patients, regardless of location of arrest or initial rhythm, with 135 return of spontaneous circulation (ROSC) and with sustained unconsciousness 136 (GCS≤7), were considered for induced hypothermia. Exclusion criteria for 137 hypothermia treatment were terminal disease, intracerebral hemorrhage, aortic 138 dissection or major trauma. 
Results

168
Eighty-four patients were included and one was excluded due to lack of all samples. 169
The final study included 83 patients with CA of mixed origin, including cardiac and 170 non-cardiac causes. Fifty-seven patients were men (69%). The median time from 171 cardiac arrest to ROSC was 20 minutes (IQR 14-30). Median APACHE II score was 172 30 (IQR 26-32), median SOFA score day 1 was 9 (IQR 8-11). Sixty-three patients 173 (76%) had an out of hospital CA of cardiac origin. Forty-two patients (51%) had a 174 good outcome and only one patient was alive at six months in the poor outcome group 175 (CPC 3). In 40 deceased patients (48%), the cause of death was classified as brain 176 injury in 29 patients, cardiac disorder in 8 and other causes in 3. 5 Patient 177 characteristics, dichotomized by good and poor outcome are shown in table 1. A total 178 of 557 samples out of a theoretical maximum of 664 were analyzed. Missing early 179 samples were largely due to transfer of patients between hospitals, or wards. The main 180 reasons for missing samples between 24-72h were patients dying, or leaving the ICU. 181
Patients with a poor outcome had significantly higher HBP-levels as early as 6h 182 (p=0.049) and 12h (p=0.01) after CA with Bonferroni corrections (x7) ( Table 2) The present study was conducted to investigate the time course of HBP, its 214 association with critical illness, infections and with outcome at six months after CA. 215
We found HBP to be elevated in a majority of patients during the first 24h after CA. 216
Plasma levels of HBP correlated with severity of critical illness, and patients with 217
223
Discrimination between the inflammatory response to infection and the 224 proinflammatory activity inherent to PCAS cannot be made with either CRP or 225 PCT. 25 As HBP has been shown to predict severe sepsis it could be hypothesized that 226 HBP-elevation in this study was due to the presence of infection. 17, 18 This was 227 thoroughly investigated using both a prospectively recorded definition, as well as two 228 retrospective definitions 25 showing that HBP was not higher among patients with 229
infection. This suggests that elevated levels of HBP after CA represent a nonspecific 230 inflammatory response as part of PCAS, rather than a specific response to infection. 231
There may indeed be several factors that affect the inflammatory activity in the CA 232 patient in the ICU, such as use of IABP and vasopressors, but most will probably be 233 concealed by the massive, systemic inflammation caused by PCAS. 234
Early elevated HBP indicated an increased likelihood for elevated lactate at 24h, with 235 a tendency towards a positive fluid balance during the same time period. The interval 236 between elevated HBP and elevated lactate, although speculative, might reflect the 237 role of HBP in the pathogenesis of critical illness as HBP has been shown to increase 238 vascular permeability causing edema and hypoperfusion. 16, 28 Early elevated HBP also 239 correlated with time to ROSC, SOFA-score day 1 and APACHE-II, indicating an 240 association with impact of the initial insult and consequent severity of critical illness. 241
The best correlation between HBP and time to ROSC was at admission (rho=0.61) 242 (Figure 3 ). Time to ROSC is a well-established prognostic factor, 29, 30 but its accuracy 243 is unreliable, therefore HBP might be used to elucidate latency to ROSC and thus 244 quantify the burden of reperfusion injury. 245
There is an increasing interest in biomarkers as adjuncts in prognostication of survival 246 and neurological outcome after CA. NSE and PCT can predict neurological outcome 247 starting at 24-48h after CA with acceptable sensitivity and specificity.
10-14 Here we 248
show that HBP may predict outcome earlier, which is consistent with pre-clinical 249 studies of HBP.
16 HBP is mainly derived from neutrophils 21 and is the only granule 250 protein in neutrophils that is released from both secretory vesicles and azurophilic 251 granules. Secretory vesicles release HBP rapidly upon neutrophil activation, while 252 azurophilic granules are mobilized slowly. The fall in HBP in the first 12h after CA is 253 thus likely due to complete initial secretion from secretory vesicles, though it may be 254 compounded by reduced leukocyte function due to hypothermia. Interestingly, the 255 median and range of HBP after CA was lower than in previous reports of patients 256 with severe sepsis and shock (analyzed in the same lab), 17, 19 where azurophilic 257 granules most likely also are activated. We hypothesize that a limited activation of 258 leukocytes after CA might hint towards a specific inflammatory response elicited by 259
CA and reperfusion injury. 260
In the study by Linder et al on HBP and severe sepsis, a cut-off value of 15ng/ml was 261 suggested (Figure 2 ) with an 88.4% positive predictive value for severe sepsis. 17 The 262 proinflammatory state inherent to PCAS probably necessitates a different reference 263 range. However, a relevant cut-off point could not be established in this study. 
